Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement
23 oct. 2023 01h00 HE
|
Mithra Pharmaceuticals
Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement Relates to the submission of a marketing approval application in JapanMarks strong...
Mithra’s Board of Directors to propose the removal of its request for change of the remuneration policy at the Special General Meeting
17 oct. 2023 01h00 HE
|
Mithra Pharmaceuticals
Mithra’s Board of Directors to propose the removal of its request for change of the remuneration policy at the Special General Meeting Liege, Belgium, 17 October 2023 – 7:00 CEST – Mithra...
Shareholder Letter
11 oct. 2023 01h15 HE
|
Mithra Pharmaceuticals
Dear Shareholders, We write to you today with a deep sense of responsibility and transparency, driven by our commitment to the principles of sound corporate governance and the long-term success of...
Mithra announces update to the agenda of its upcoming special general shareholders’ meeting
11 oct. 2023 01h00 HE
|
Mithra Pharmaceuticals
Liege, Belgium, 11 October 2023 – 7:00 CEST – Mithra (Euronext Brussels: MITRA) (the "Company"), a company dedicated to Women’s Health, today announces that it has received a...
Mithra to Hold Presentations on Key Role of Estrogens in Women’s Health, Including Estetrol (E4), at FIGO World Congress
10 oct. 2023 12h00 HE
|
Mithra Pharmaceuticals
Mithra to hold joint symposium with partner Gedeon Richter on 11 OctoberFour leading experts will outline why estrogens are critical in contraception and postmenopausal symptomsData show promising...
Mithra Provides an Update in the Context of Recent Market Developments
05 oct. 2023 01h00 HE
|
Mithra Pharmaceuticals
Mithra Provides an Update in the Context of Recent Market Developments Financial results show Mithra has solid financial foundation and multiple options to financeShareholder meetings called to...
Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023
27 sept. 2023 01h00 HE
|
Mithra Pharmaceuticals
Independent global leaders in medical research on women’s health, Professor Amanda Black and Professor Wulf Utian, to deliver two presentations each on E4E4 is a key active pharmaceutical ingredient...
Mithra Financial Results for First-Half 2023
26 sept. 2023 01h00 HE
|
Mithra Pharmaceuticals
Mithra Financial Results for First-Half 2023 Good progress on strategy to strengthen balance sheet and refocus on innovative R&DRevenues EUR 7.0 million, driven by Estelle® and Myring®...
Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d'une conférence web le 26 septembre à 14 h 00 CET
22 sept. 2023 07h30 HE
|
Mithra Pharmaceuticals
Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d'une conférence web le 26 septembre à 14 h 00 CET Liège, Belgique, 22 septembre 2023 – 13 h 30 CET –...
Information on the total number of voting rights (denominator)
21 sept. 2023 11h55 HE
|
Mithra Pharmaceuticals
Information on the total number of voting rights (denominator) Liege, Belgium, 21 September 2023 – 5:45 pm CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today...